Abstract
Telaprevir, a protease inhibitor, was recently approved for management of Chronic Hepatits C (CHC) due to HCV genotype 1. Various RCTs have demonstarted increased incidence of cutaneous adverse effects with use of Telaprevir. Herein, we report two cases of drug rash with eosinophilia and systemic symptoms (DRESS) secondary to Telaprevir use.
| Original language | English |
|---|---|
| Pages (from-to) | 199-200 |
| Number of pages | 2 |
| Journal | Journal of Drugs in Dermatology |
| Volume | 13 |
| Issue number | 2 |
| State | Published - Feb 2014 |